Malignant mesothelioma (MM) shows frequent inactivation of the neurofibromatosis type 2 (NF2) --tumor-suppressor gene. Recent studies have documented that the Hippo signaling pathway, a downstream cascade of Merlin (a product of NF2), has a key role in organ size control and carcinogenesis by regulating cell proliferation and apoptosis. We previously reported that MMs show overexpression of Yes-associated protein (YAP) transcriptional coactivator, the main downstream effector of the Hippo signaling pathway, which results from the inactivation of NF2, LATS2 and/or SAV1 genes (the latter two encoding core components of the mammalian Hippo pathway) or amplification of YAP itself. However, the detailed roles of YAP remain unclear, especially the target genes of YAP that enhance MM cell growth and survival. Here, we demonstrated that YAP-knockdown inhibited cell motility, invasion and anchorage-independent growth as well as cell proliferation of MM cells in vitro. We analyzed genes commonly regulated by YAP in three MM cell lines with constitutive YAP-activation, and found that the major subsets of YAP-upregulating genes encode cell cycle regulators. Among them, YAP directly induced the transcription of CCND1 and FOXM1, in cooperation with TEAD transcription factor. We also found that knockdown of CCND1 and FOXM1 suppressed MM cell proliferation, although the inhibitory effects were less evident than those of YAP knockdown. These results indicate that constitutive YAP activation in MM cells promotes cell cycle progression giving more aggressive phenotypes to MM cells.
INTRODUCTION
Malignant mesothelioma (MM) is one of the most aggressive neoplasms, which is caused by asbestos exposure. 1, 2 It is usually resistant to conventional therapies, and the prognosis of patients is very poor. The median survival of malignant pleural mesothelioma patients after diagnosis is 7 --11 months. 1, 3, 4 There is a 30 --40 year interval before clinical presentation of the tumor after asbestos exposure. 5 While the long latency of the disease implies that multiple genetic and epigenetic alterations might be required for MM progression, 6 the detailed molecular pathogenesis of MM has not been well understood.
Among the limited number of genes that are frequently mutated in MMs, inactivation of p16 INK4a /p14 ARF is detected in over 70% of MMs. 7 The NF2 gene, which is responsible for the NF2 familial cancer syndrome, has been shown to be inactivated in 40 --50% of MMs. 8, 9 A recent study has also indicated that 23% of MM cases had an inactivating mutation of BAP1, which encodes a nuclear deubiquitinase. 10, 11 The NF2 gene encodes Merlin, which is a membranecytoskeleton-associated protein with four-point-one, ezrin, radixin and moesin domain, and acts as a tumor suppressor. 12 One of the downstream signaling cascades regulated by Merlin is the Hippo signaling pathway, which is conserved from Drosophila to mammalians. 13 --15 In MM cells, besides the NF2 mutation, genetic alterations in the components of the Hippo signaling pathway have also been identified recently, including inactivating mutations of large tumor suppressor 1 (LATS1), LATS2 and SAV1, and amplification of Yes-associated protein (YAP). 10, 16, 17 Together with NF2 mutation, MM shows frequent Merlin-Hippo pathway inactivation, which leads to YAP activation in over 70% of MM cases. 18 Studies have shown that the Hippo signaling pathway is involved in the cell cycle regulation and the control of organ size. 19, 20 The dysregulation of this pathway, which leads to constitutive YAP activation, induces the oncogenic transformation in cooperation with distinct transcription factors such as TEAD family members. 21 --24 Overexpression, especially dominant expression in the nuclei compared with the cytoplasm of tumor cells and the oncogenic roles of YAP have been shown in various types of human malignancies. 25 --29 On the other hand, the antiproliferative or apoptosis-inducing function of YAP has also been demonstrated in the context of DNA damage or cellular stress, which induces its binding of YAP with other transcription factors such as p73, a paralog of p53 tumor suppressor. 30 --32 We previously showed that YAP promoted cell proliferation 17 and exogenous LATS2 inhibited cell proliferation via induction of YAP phosphorylation in MM cells. 16 However, the detailed characteristics of YAP oncogenic properties remain unclear, including the exact target genes that are inducible by YAP activation in MM cells. In this study, we aimed to identify the target genes of YAP in MM cells to elaborate how YAP induces the MM-cell malignant phenotypes. We found that cell cycle-regulating genes, including CCDN1 and FOXM1, are induced by YAP, suggesting that the dysregulation of cell cycle regulation is one of the key alterations in which MM cells acquire malignancy by YAP activation.
RESULTS AND DISCUSSION
Knockdown of YAP suppressed oncogenic properties of MM cells We previously reported that several MM cell lines with NF2 and/or LATS2 mutations have constitutive YAP activation with low-level phosphorylation of YAP (S127). 16 Using western blot analysis with a panel of 23 MM cell lines, we confirmed that 16 (70%) cell lines showed lower levels of pYAP-S127 than MeT-5A, a transformed normal mesothelial cell line (Supplementary Figure 1) . Among them, we selected three MM cell lines with constitutive YAP activation for further analyses; NCI-H290 with NF2 inactivation, and Y-MESO-27 and Y-MESO-30 with LATS2 inactivation. As we previously showed that YAP inhibition suppressed NCI-H290 cell proliferation, 17 we first confirmed that a newly Identification of YAP-regulating genes by microarray-based expression profiling analysis As for the target genes of YAP orthologs, cyclin E, Diap1 and bantam microRNA have been identified for Drosophila Yokie. 19 For mammalian YAP, although several genes including the connective tissue growth factor (CTGF) gene were shown as direct target genes of YAP, 24 other possible candidate target genes for mammalian counterparts do not seem to be really substantiated yet or even excluded, implying that YAP target genes vary among different species as well as among different cell types.
To identify the genes inducible for expression by YAP and responsible for MM cell proliferation, we performed microarraybased expression profiling analysis of the three MM cell lines after YAP knockdown. We found that 1381, 650 and 2097 genes were downregulated to equal or less than 0.5 in the NCI-H290, Y-MESO-27 and Y-MESO-30 cells, respectively, compared with each counterpart cell with the control vector (data not shown). We found that 228 genes were commonly downregulated by YAP knockdown, suggesting that this gene set includes strong candidates for YAP target genes in MM cells (Supplementary Table 1 ). To characterize the 228 genes, we performed gene ontology analysis and found that the large portion of YAP-regulatory genes is associated with cell cycle regulation ( Table 1) . Subsequent pathway analysis revealed that the pathways of transcriptional regulation by RB/E2F and FOXM were most significantly correlated (Table 1) .
Meanwhile, our results revealed that 156 genes were commonly upregulated after YAP knockdown over twofold (Supplementary Table 1 ). Gene ontology and pathway analyses indicated that genes involved in wounding, inflammation and cell --extracellular matrix adhesion were upregulated, suggesting that suppression of these signaling pathways might also contribute to malignant phenotypes of MM cells by YAP activation, albeit their expressions might be indirectly suppressed (Supplementary Table 2 ).
YAP regulates CCND1 and FOXM1 transcription directly in cooperation with TEAD Among the identified cell cycle regulatory genes, we focused on CCND1, a G1 cyclin-regulating RB/E2F pathway, and FOXM1, a transcription factor targeting both G1/S and G2/M progression regulators. CCND1 and FOXM1 were found to be commonly downregulated in the three cell lines from 0.13 to 0.48 and from 0.13-to 0.42-changes, respectively (Supplementary Table 1 ). Moreover, their promoter regions were also likely to harbor a putative recognition motif of TEAD, a transcriptional factor that binds to YAP.
To determine whether YAP regulates transcription of CCND1 and FOXM1 directly in MM cells, we carried out a chromatin immunoprecipitation assay. We prepared a primer set for the proximal promoter region of both genes to include the putative TEAD recognition motif 33 ( Figure 2a ). When precipitated with anti-YAP antibody, we detected positive PCR products of the proximal promoter regions of both genes, which indicated the direct binding of YAP to the CCND1 and FOXM1 proximal promoter regions (Figure 2b ), although they were not detected in the distal regions (data not shown).
Next, to determine whether YAP induces transcription of CCND1 and FOXM1, and then transcription is further enhanced by exogenous TEAD transcription factor, we performed luciferase reporter assay for the promoter regions of these genes (Figure 2a ) with YAP wild type and its constitutively active form, YAP S127A. We found that cotransduction of wild-type TEAD4 with YAP wild type or the active mutant form significantly induced both CCND1 and FOXM1 promoter activities. On the other hand, cotransduction of other mutant forms including YAP S94A 24 or TEAD4DCt, 34 both of which were thought to disrupt the YAP-TEAD interaction, did not show the enhancement of luciferase activity (Figures 2c and d) .
These results provided support for the notion that CCND1 and FOXM1 might be the direct target genes of YAP in MM cells. Consistent with our observations, induction of CCND1 by YAP has also been suggested by other studies. For example, in vertebrate neural tube development, YAP and TEAD promoted cell cycle progression by inducing CCND1. 21 As an upstream suppressive regulator of YAP, Merlin was also shown to inhibit CCND1 expression by using NF2-deficient MM cells. 35 Although those reports did not refer to transcriptional regulation of CCND1 by YAP, they demonstrated a contribution of Hippo signaling pathway to CCND1 regulation, which our present findings corroborate.
YAP depletion suppressed cell cycle-promoting gene expressions in MM cells
The gene ontology analysis based on the microarray-based expression profiling suggested a significant contribution of YAP to the cell cycle process in MM cells. Based on our previous data indicating G1 cell cycle arrest in NCI-H290 cells by YAP knockdown, 17 we studied the status of cell cycle and expressions of cell cycle-promoting genes in a time-dependent manner after YAPshRNA lentivirus infection. We found that G1 cell cycle arrest occurred at as early as 48 h, and the population of G1 cell cycle arrest increased at 72 h (Figure 3a) . With quantitative real-time RT-PCR analysis, suppression of the CCND1 gene expression was revealed to follow the downregulation of YAP as expected (Figure 3c) . Consistent with the expression array analysis, other cell cycle-promoting genes including E2F1, Aurora kinase B (AURKB), Polo-like kinase 1 (PLK1) and NIMA-related kinase 2 (NEK2), also showed the decrease in the expression levels according to YAP-downregulation (Figure 3c ). However, other irrelevant genes such as SMAD3 did not show any decrease (data not shown). These results suggested that, together with YAPdirect target genes of CCND1 and FOXM1, other cell-promoting genes are also involved in the dysregulated cell cycle machinery in YAP-activated MM cells.
Additionally, we observed that YAP-knockdown increased subG1 population of the cells in flow cytometric analysis (Figure 3b ) and affected the expression levels of several apoptotic-related genes, including the downregulation of BIRC5 (also known as survivin), an anti-apoptotic gene, and upregulated the one of BCL2L11 (also known as BIM), a pro-apoptotic gene (Supplementary Table 2 ). In a flow cytometric assay with ) and protein A beads, immunoprecipitated chromatin were decross-linked. Recruited DNA was subjected to PCR using primer sets for proximal promoter regions of CCND1 and FOXM1, and PCR products were electrophoresed in agarose gel. (Lower panel) Note that amounts of PCR products from the chromatin, which was precipitated with the anti-YAP antibody, were suppressed by pretreatment with siYAP. (c, d) For reporter assay, MeT-5A cells were transfected with the pGL3 basic firefly luciferase reporter plasmid with the CCND1 or FOXM1 promoter region by using FuGENE 6 transfection reagent (Roche, Mannheim, Germany). Renilla luciferase plasmid was also transfected for internal control. Thirty-six hours later, cells were lysed and subjected to dual-luciferase assay (TOYO INK, Tokyo, Japan). The promoter activities were enhanced with combined transduction of TEAD4 WT with wild type (WT) or constitutively activated forms of YAP (YAP S127A Figure 2) . Although these data suggested apoptosis induction in MM cells, we did not find significant caspase activation with western blot analysis probably due to a relatively small population of MM cells that underwent apoptosis (data not shown). Thus, further studies may be warranted to clarify the underlying mechanism and significance of cell death by YAP-knockdown in MM cells.
CCND1 contributes to G1/S transition in MM cells
To determine whether knockdown of individual cell cycle specific genes regulated by YAP is sufficient to induce G1 cell cycle arrest in MM cells, we performed cell cycle analysis of NCI-H290 cells with knockdown of CCND1 or FOXM1. After transduction of CCND1-sh, we found that the cell population of G1 phase increased and that of S phase decreased compared with the control cell (Figure 3d ), although the effect was weaker than that of YAP-sh. However, the effect of FOXM1-sh on cell cycle progression was not clear (Figure 3d) .
Finally, to evaluate proliferative roles of CCND1 or FOXM1 as YAP transcriptional targets in MM cells, we knocked down CCND1 and FOXM1 and performed proliferation analysis. The depletion of CCND1 and FOXM1 caused modest suppression compared with YAP depletion, though the decrease of proliferation was larger in CCND1 depletion than FOXM1 depletion at 26% and 14%, respectively (Figures 3e and f) . Taken together, these results suggested that YAP contributes to expression of a wide range of cell cycle-promoting genes and induces MM cell proliferation, although knockdown of individual YAP target genes shows moderate effects.
In conclusion, we showed that YAP induces multiple gene expression, which includes cell cycle-promoting genes such as CCND1 and FOXM1 in MM cells. Our findings thus serve to elucidate some important aspects of dysregulated cell cycle control mechanisms in MM cells through YAP activation. As individual inhibition of YAP target genes did not suppress MM proliferation sufficiently, we speculate that a wide range of genes evoked by YAP activation induce MM cell proliferation and progression as a whole. Thus, our results suggest that YAP itself may be a key target molecule for the development of a new molecular target therapy for MM.
